Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/469)
-
Publication number: 20130289083Abstract: Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprisType: ApplicationFiled: March 13, 2013Publication date: October 31, 2013Inventor: NewLink Genetics Corporation
-
Patent number: 8569279Abstract: Disclosed is a method for modulating a claudin-mediated function in a mammalian subject which comprises administering to a subject in need thereof an effective amount of a specific fatty acid derivative. The application also discloses a method for treating a dermatological disease and a method for modulating an expression of a claudin in a mammalian subject using the same fatty acid derivative as above.Type: GrantFiled: August 10, 2010Date of Patent: October 29, 2013Assignees: Sucampo AG, Osaka UniversityInventors: Ryuji Ueno, Sachiko Tsukita
-
Publication number: 20130281394Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: October 24, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
-
Publication number: 20130281453Abstract: Serine hydrolases are implicated in malconditions such as cancer, central nervous system disorders, cardiovascular disorders, obesity, and metabolic disorders. Many serine hydrolases expressed in proteomic libraries are of unknown function in vivo. Compounds identified through library versus library screening can be used for treatment of malconditions associated with the specific serine hydrolase KIAA1363 (also known as AADACL1). A library of inhibitors of KIAA1363 was prepared and candidate compounds were identified as a potent inhibitors having submicromolar IC50 values. An exemplary compound of the invention was shown to be an effective inhibitor of prostate cancer pathogenesis. Other inhibitory compounds of the invention comprising fluorophore groups are shown to be effective in spatial and temporal localization of the serine hydrolase in cells and tissues.Type: ApplicationFiled: October 21, 2011Publication date: October 24, 2013Applicant: The Scripps Research InstituteInventors: Benjamin Cravatt, Daniel Nomura, Jae W. Chang, Raymond E. Moellering, Dan Bachovehin, Weiwei Li
-
Publication number: 20130274261Abstract: Methods of treating pulmonary hypertension are disclosed. Particular methods comprise the administration of a tryptophan hydroxylase inhibitor and a prostacyclin. Pharmaceutical formulations are also disclosed.Type: ApplicationFiled: March 18, 2013Publication date: October 17, 2013Inventor: Arthur T. SANDS
-
Publication number: 20130274326Abstract: The invention relates to an extract of Euodia suaveolens Scheff. The invention is characterized in that the extract is obtained from the airborne portions of the plant by means of at least one extraction step using an organic or hydro-alcoholic solvent, and in that it comprises evodone at a concentration of between 0.1 and 35% by weight of the total weight of the extract, and in that it has an insect repellent activity. The invention also relates to a repellent composition, characterized in that it comprises, in a cosmetically acceptable medium, evodone at a concentration of between 0.1 and 25% by weight of the total weight of the composition, and to the use of evodone as an active agent for repelling insects, in particular mosquitoes and more particularly the European/Mediterranean mosquitoes of the Aedes aegypti species.Type: ApplicationFiled: June 7, 2013Publication date: October 17, 2013Inventors: Marina Humbert, Sophie Lavoine-Hanneguelle
-
Publication number: 20130274325Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.Type: ApplicationFiled: March 12, 2013Publication date: October 17, 2013Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
-
Publication number: 20130267589Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.Type: ApplicationFiled: June 5, 2013Publication date: October 10, 2013Inventors: Tsuneo YASUMA, Nobuyuki NEGORO
-
Patent number: 8552058Abstract: The invention discloses the application of l-n-butylphthalide as formula (I) in preparing a medicine for preventing and treating dementia, in special Alzheimer's disease and vascular dementia.Type: GrantFiled: June 18, 2004Date of Patent: October 8, 2013Assignee: CSPC Zhongqi Pharmaceutical Technology (Shijazhuang) Co., Ltd.Inventors: Yipu Feng, Xiaoliang Wang, Rongduan Wang, Ying Peng, Liying Yang, Jinghua Yang, Jingguo Sun, Zhankun Yang
-
Patent number: 8552032Abstract: The present invention is directed to novel bicyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.Type: GrantFiled: December 16, 2010Date of Patent: October 8, 2013Assignee: Janssen Pharmaceutica NVInventors: Edward C. Lawson, Dennis J. Hlasta, Shyamali Ghosh, Renee L. DesJarlais, Carsten Schubert
-
Publication number: 20130261177Abstract: The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.Type: ApplicationFiled: September 30, 2011Publication date: October 3, 2013Applicant: RIGSHOSPITALETInventors: Pär Johansson, Sisse Rye Ostrowski
-
Patent number: 8546446Abstract: Disclosed are isosorbide derivatives according to the following general formula wherein R represent a hydrogen atom, or an alkyl group with 6 to 22 C-atoms, or an acyl group, or a group X—SO3M, and M stands for a cation, a hydrogen atom or an alkali metal atom or an ammonium or an alkylammonium ion, and X represents an alkoxylated derivative (AO)n wherein AO represents a group C2H4O, or C3H6O, or any mixtures thereof, and the index n is zero or 1 to 20, and p represents a number between 1 and 10, preferably between 1 and 4, and the use thereof to prepare cleansers, detergents, personal care compositions, or cosmetic compositions.Type: GrantFiled: June 18, 2010Date of Patent: October 1, 2013Assignee: Cognis IP Management GmbHInventors: Ansgar Behler, Catherine Breffa, Hans-Christian Raths, Thorsten Löhl
-
Publication number: 20130252937Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.Type: ApplicationFiled: March 14, 2013Publication date: September 26, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Matthias ECKHARDT, Sara FRATTINI, Dieter HAMPRECHT, Frank HIMMELSBACH, Elke LANGKOPF, Iain LINGARD, Stefan PETERS, Holger WAGNER
-
Publication number: 20130245004Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.Type: ApplicationFiled: May 9, 2013Publication date: September 19, 2013Applicant: Synchroneuron Inc.Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong
-
Publication number: 20130244959Abstract: The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-?1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.Type: ApplicationFiled: November 17, 2011Publication date: September 19, 2013Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Kyung Seop Ahn, Ha Young Jang, Sei Ryang Oh, Hyeong Kyu Lee, Ok-Kyoung Kwon, Semi Kim, Jung Hee Kim, Doo-Young Kim
-
Publication number: 20130245115Abstract: The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent.Type: ApplicationFiled: May 6, 2013Publication date: September 19, 2013Applicant: SANOFIInventors: Bernard ABRAMOVICI, Stephane BEILLES, Sandra CHAMBONNET, Jean-Claude GAUTIER
-
Publication number: 20130244952Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: ApplicationFiled: October 11, 2012Publication date: September 19, 2013Applicant: Abraxis BioScience, LLCInventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
-
Patent number: 8536350Abstract: The invention relates to a new process for the preparation of dronedarone and its salts, in particular a synthesis process which allows said compound and its salts to be obtained with good yields, high purity and in an industrially expedient manner; the invention also concerns a new synthesis intermediate.Type: GrantFiled: January 26, 2011Date of Patent: September 17, 2013Assignee: Laboratorio Chimico Internazionale S.p.A.Inventors: Mara Sada, Antonio Nardi, Stefano Maiorana
-
Publication number: 20130237536Abstract: Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.Type: ApplicationFiled: April 26, 2013Publication date: September 12, 2013Applicant: The Cleveland Clinic FoundationInventors: Mohamed Naguib Attala, Philippe Diaz
-
Publication number: 20130236573Abstract: The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least on antidepressant.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Inventors: Jaskaran Singh, Ivo Caers
-
Publication number: 20130237571Abstract: The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.Type: ApplicationFiled: July 20, 2011Publication date: September 12, 2013Applicant: Conexios Life Sciences PVT. LTD.Inventors: Jagannath Madanahalli Ranganath Rao, Nagarajan Arumugam, Mohd Mudabbir Ansari, Chandrasekhas Gudla, Shanmugam Pachiyappan, Manivannan Ramalingam, Jenson George, George Fernanda Arul, Kenchegowda Bommegowda, Y, Sathesh Kumar Angupillai, Ramamoorthy Kottamalai, Pradeep Jidugu, Shivanageshwara Rao, D
-
Publication number: 20130237560Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.Type: ApplicationFiled: March 15, 2013Publication date: September 12, 2013Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado
-
Publication number: 20130225673Abstract: A compound represented by the general Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a pro-drug thereof, a deuterated radio-labeled analog thereof, and mixtures of any of the foregoing, wherein: A-K are individually selected from carbon or nitrogen; X?—O, —NR1, or —S; R1-11 are individually selected from the group consisting of —H, C1-C6 alkyl, C6-C14 aryl, substituted C6-C14 aryl, C1-C14-alkoxy, halogen, hydroxyl, carboxy, cyano, C1-C6-alkanoyloxy, C1-C6-alkylthio, C1-C6-alkylsulfonyl, trifluoromethyl, hydroxy, C2-C6-alkoxycarbonyl, C2-C6-alkanoylamino, —O—R12, S—R12, —SO2—R12, —NHSO2R12 and —NHCO2R12, wherein R12 is phenyl, naphthyl, or phenyl or naphthly substituted with one to three groups selected from C1-C6-alkyl, C6-C10 aryl, C1-C6-alkoxy and halogen, and C4-C20 hydroxyheteroaryl wherein the heteroatoms are selected from the group consisting of sulfur, nitrogen, and oxygen.Type: ApplicationFiled: October 6, 2011Publication date: August 29, 2013Applicant: J-PHARMA CO., LTD.Inventors: Michael F. Wempe, Hitoshi Endou
-
Publication number: 20130217763Abstract: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.Type: ApplicationFiled: March 19, 2013Publication date: August 22, 2013Applicant: SANOFIInventor: SANOFI
-
Publication number: 20130217730Abstract: The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or chemoprevention of cancer, aging related diseases or processes, diabetes and neurodegenerative diseases.Type: ApplicationFiled: May 10, 2011Publication date: August 22, 2013Applicant: IKERCHEM, S.L.Inventors: Fernando Pedro Cossio Mora, Leire Lidia Arias Echeverría, Yosu Ion Vara Zalazar, Eneko Aldaba Arévalo, Eider San Sebastián Larzabal, Aizpea Zubia Olascoaga
-
Publication number: 20130217704Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.Type: ApplicationFiled: April 1, 2013Publication date: August 22, 2013Inventor: Sequoia Pharmaceuticals, Inc.
-
Publication number: 20130217615Abstract: A method is provided for treating depression, and particularly major depression,by administering an effective amount of an SSRI medication that is augmented by administering an effective amount of an amphetamine prodrug, such as lisdexamfetamine, to patients receiving an SSRI medication. In particular, the amphetamine prodrug is administered to augment the effects of an SSRI medication in patients who respond poorly to the effects of the SSRI medication.Type: ApplicationFiled: October 28, 2011Publication date: August 22, 2013Applicant: SHIRE LLCInventors: Robert A. Lasser, Timothy M. Whitaker, Jeff Jonas
-
Patent number: 8513254Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.Type: GrantFiled: December 20, 2010Date of Patent: August 20, 2013Assignee: Gilead Sciences, Inc.Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
-
Patent number: 8507553Abstract: The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory learning injury caused by neuronal cell injury using transformed animal model with beta-amyloid precursor gene, therefore the compounds can be useful in treating or preventing cognitive function disorder.Type: GrantFiled: June 5, 2012Date of Patent: August 13, 2013Assignees: Daewoong Pharmaceutical Co., Ltd., Medifron DBT Co., Ltd.Inventors: Dong Wook Kang, Jee Woo Lee, Young Ho Kim, Hee Kim, Hee Jin Ha, Eun Joo Nam, Chan Mi Joung
-
Publication number: 20130203688Abstract: The present document describes a nutraceutical or cosmeceutical composition for the prophylaxis of an ailment comprising a therapeutically effective amount of a sugar plant syrup filtration residue in association with a pharmaceutically acceptable carrier. The present document also describes a nutraceutical or cosmeceutical composition for improving health condition of skin. The present document describes a method of producing a sugar plant syrup-derived product; wherein the improvement is characterized in the step of: collecting a sugar plant syrup residue during the production of sugar or syrup to produce a syrup-derived by-product.Type: ApplicationFiled: August 19, 2011Publication date: August 8, 2013Applicant: FÉDÉRATION DES PRODUCTEURS ACÉRI-COLES DU QUÉBECInventors: Julie Barbeau, Geneviève Béland
-
Patent number: 8501804Abstract: The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: October 26, 2009Date of Patent: August 6, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Makoto Kamata, Tohru Yamashita, Asato Kina, Michiko Amano
-
Publication number: 20130197076Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.Type: ApplicationFiled: January 25, 2013Publication date: August 1, 2013Applicant: Vanda Pharmaceuticals, Inc.Inventor: Vanda Pharmaceuticals, Inc.
-
Publication number: 20130190393Abstract: The described subject matter relates to the use of incensole, incensole acetate, and derivatives thereof, for the treatment, prevention or amelioration of diseases or conditions, including inflammatory-associated conditions; a disease or condition where neuroprotection is required; and a disease or condition selected from depression, anxiety, obsessive compulsive behaviors, deterioration in cognitive function, and deterioration in neurobehavioral function. Pharmaceutical compositions and method of treatment, prevention or amelioration of the above-mentioned diseases or conditions are also provided.Type: ApplicationFiled: December 4, 2012Publication date: July 25, 2013Applicants: ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.Inventors: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD., ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD.
-
Patent number: 8491872Abstract: Cinnamic acid-based oligomers and therapeutic uses thereof are provided. The oligomers are used as anti-inflammation agents, inhibitors of elastase and anti-oxidants, and in some cases (e.g. the treatment of lung disorders such as lung cancer) all three activities are simultaneously beneficial. Subsets of the oligomers (e.g. ?-O4 and ?-5 trimers and tetramers) are used as anticoagulants.Type: GrantFiled: August 4, 2009Date of Patent: July 23, 2013Assignee: Virginia Commonwealth UniversityInventors: Umesh R. Desai, Brian L. Henry, Aiye Liang, Jay Thakkar, John B. Mangrum, Ivo Torres Filho, Bruce D. Spiess, Masahiro Sakagami, Bhawana Saluja
-
Publication number: 20130178490Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more carbamate compound(s) selected from Group (A) shows an excellent controlling activity on a pest.Type: ApplicationFiled: October 13, 2011Publication date: July 11, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka
-
Patent number: 8481088Abstract: The invention relates to an extract of Euodia suaveolens Scheff. The invention is characterized in that the extract is obtained from the airborne portions of the plant by means of at least one extraction step using an organic or hydro-alcoholic solvent, and in that it comprises evodone at a concentration of between 0.1 and 35% by weight of the total weight of the extract, and in that it has an insect repellent activity. The invention also relates to a repellent composition, characterized in that it comprises, in a cosmetically acceptable medium, evodone at a concentration of between 0.1 and 25% by weight of the total weight of the composition, and to the use of evodone as an active agent for repelling insects, in particular mosquitoes and more particularly the European/Mediterranean mosquitoes of the Aedes aegypti species.Type: GrantFiled: March 12, 2010Date of Patent: July 9, 2013Assignee: CharabotInventors: Marina Humbert, Sophie Lavoine-Hanneguelle
-
Publication number: 20130172390Abstract: The present invention relates to halogen-substituted amide derivatives of the general formula (I) in which R1 to R6, Q1 to Q8, A, V, W, X, Y, n and m are each defined as described in the description—and to a process for preparation thereof and to the use thereof as insecticides and acaricides.Type: ApplicationFiled: September 14, 2012Publication date: July 4, 2013Applicant: Bayer Intellectual Property GmbHInventors: Markus Heil, Eike Kevin Heilmann, Alexander Sudau, Tobias Kapferer, Friedrich August Mühlthau, Peter Jeschke, Arnd Voerste, Ulrich Görgens, Klaus Raming, Ulrich Ebbinghaus-Kintscher, Mark Drewes, Martin Adamczewski, Angela Becker
-
Patent number: 8470878Abstract: The present invention relates to compounds: and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases like cancer and inflammation.Type: GrantFiled: June 7, 2012Date of Patent: June 25, 2013Assignee: Novartis AGInventors: Ramulu Poddutoori, Can Wang, Xianglin Zhao
-
Publication number: 20130143960Abstract: Serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation.Type: ApplicationFiled: February 4, 2013Publication date: June 6, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventor: Ramot at Tel-Aviv University Ltd.
-
Publication number: 20130143867Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.Type: ApplicationFiled: January 18, 2013Publication date: June 6, 2013Applicant: SYCHRONEURON INC.Inventor: SYCHRONEURON INC.
-
Publication number: 20130142758Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.Type: ApplicationFiled: January 17, 2013Publication date: June 6, 2013Applicant: PHARMACYCLICS, INC.Inventor: PHARMACYCLICS, INC.
-
Publication number: 20130143869Abstract: Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction and/or prevention of subcutaneous adipose tissue with improved effectiveness and better reproducible activity.Type: ApplicationFiled: July 14, 2011Publication date: June 6, 2013Applicant: Merz Pharma GmbH & CO. KGaAInventors: Kevin Kiehm, Bernhard Hauptmeier, Harry Abts, Peter Boderke
-
Publication number: 20130142849Abstract: The present invention relates to controlled release formulation of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of controlled release formulations of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day.Type: ApplicationFiled: August 13, 2011Publication date: June 6, 2013Applicant: LUPIN LIMITEDInventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirish Kulkarni
-
Publication number: 20130143861Abstract: The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of budiodarone and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of budiodarone may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling.Type: ApplicationFiled: February 4, 2013Publication date: June 6, 2013Applicant: ARMETHEON, INC.Inventor: Armetheon, Inc.
-
Patent number: 8455542Abstract: The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory learning injury caused by neuronal cell injury using transformed animal model with beta-amyloid precursor gene, therefore the compounds can be useful in treating or preventing cognitive function disorder.Type: GrantFiled: June 5, 2012Date of Patent: June 4, 2013Assignees: Daewoong Pharmaceutical Co., Ltd., Medifron DBT Co., Ltd.Inventors: Dong Wook Kang, Jee Woo Lee, Young Ho Kim, Hee Kim, Hee Jin Ha, Eun Joo Nam, Chan Mi Joung
-
Publication number: 20130123353Abstract: A dronedarone solid dispersion and preparation method thereof are disclosed. The solid dispersion is composed of active ingredient dronedarone or its pharmaceutically acceptable salt and a carrier material, wherein the carrier material is povidone, copovidone, hydroxypropyl cellulose, or a mixture thereof.Type: ApplicationFiled: May 31, 2011Publication date: May 16, 2013Applicant: JIANGSU HENGRUI MEDICINE CO., LTD.Inventors: Piaoyang Sun, Kai Pan, Yuxia Wu
-
Publication number: 20130123326Abstract: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.Type: ApplicationFiled: January 4, 2013Publication date: May 16, 2013Applicants: REGION MIDTJYLLAND, AARHUS UNIVERSITETInventors: AARHUS UNIVERSITET, REGION MIDTJYLLAND
-
Publication number: 20130123203Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.Type: ApplicationFiled: October 31, 2012Publication date: May 16, 2013Inventors: Paul Talalay, Andrew W. Zimmerman, Kirby D. Smith
-
Patent number: 8440832Abstract: Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.Type: GrantFiled: July 14, 2008Date of Patent: May 14, 2013Assignee: Board of Regents, The University of Texas SystemInventors: Mohamed Naguib Attala, Philippe Diaz
-
Publication number: 20130116316Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.Type: ApplicationFiled: November 20, 2012Publication date: May 9, 2013Applicant: SANOFIInventor: SANOFI